Subscribe
Sign in
Home
Archive
About
Latest
Top
Discussions
Response Rate Tricks in Oncology: RAS inhibitors on the spot again...
Response Rate is a measure of anti-cancer drug activity. It's more reliable in early phase trials than PFS estimates ... yet to be analyzed with great…
Jul 19
•
Vinay Prasad
and
Timothée Olivier
20
Share this post
Response Rate Tricks in Oncology: RAS inhibitors on the spot again...
www.drugdevletter.com
Copy link
Facebook
Email
Note
Other
4
Project Orbis — harmonizing up or down?
By Kristina Jenei
Jul 12
9
Share this post
Project Orbis — harmonizing up or down?
www.drugdevletter.com
Copy link
Facebook
Email
Note
Other
Eli Lilly's Court Victory: Dutch Agency Must Reevaluate Abemaciclib Amid Controversy
Eli Lilly’s court appeal to override the negative assessment of abemaciclib in the Netherlands
Jul 7
•
Sahar van Waalwijk
64
Share this post
Eli Lilly's Court Victory: Dutch Agency Must Reevaluate Abemaciclib Amid Controversy
www.drugdevletter.com
Copy link
Facebook
Email
Note
Other
12
CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms
This is the title of our new paper out in the European Journal of Cancer!
Jul 2
•
Vinay Prasad
,
Alyson Haslam
, and
Timothée Olivier
14
Share this post
CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms
www.drugdevletter.com
Copy link
Facebook
Email
Note
Other
3
June 2024
Are Patient Advocacy Groups Free from Industry Influence?
Find the results of our new paper in the Journal of Cancer Policy.
Jun 30
•
John-John Schnog
11
Share this post
Are Patient Advocacy Groups Free from Industry Influence?
www.drugdevletter.com
Copy link
Facebook
Email
Note
Other
1
THEOREMM - A Novel Framework for Cancer Registration Trials
"Trials in HEmatology and Oncology REviewed by Metaresearch Methods"
Jun 27
•
Vinay Prasad
and
Timothée Olivier
8
Share this post
THEOREMM - A Novel Framework for Cancer Registration Trials
www.drugdevletter.com
Copy link
Facebook
Email
Note
Other
Should the LAURA trial change our practice, and how? A PRO-CON debate!
Maintenance osimertinib in unresectable stage III EGFR-mutant cancer.
Jun 26
•
Vinay Prasad
and
Timothée Olivier
11
Share this post
Should the LAURA trial change our practice, and how? A PRO-CON debate!
www.drugdevletter.com
Copy link
Facebook
Email
Note
Other
Postrecurrence treatment in neo/adjuvant trials.
Is it better to treat all patients early on, or to spare those who are already cured and only treat those who relapse?
Jun 20
•
Timothée Olivier
11
Share this post
Postrecurrence treatment in neo/adjuvant trials.
www.drugdevletter.com
Copy link
Facebook
Email
Note
Other
EDITOR'S PICK: Overdiagnosis and Overtreatment in Melanoma.
A paper advocating against routine skin screening "for all".
Jun 18
•
Vinay Prasad
and
Timothée Olivier
30
Share this post
EDITOR'S PICK: Overdiagnosis and Overtreatment in Melanoma.
www.drugdevletter.com
Copy link
Facebook
Email
Note
Other
Special post for our French-speaking followers!
How to interpret oncology randomized clinical trials... in french!
Jun 12
•
Timothée Olivier
7
Share this post
Special post for our French-speaking followers!
www.drugdevletter.com
Copy link
Facebook
Email
Note
Other
Special post-ASCO 2024 edition !
Timothee Olivier and I discuss the top ASCO 2024 abstracts!
Jun 9
•
Vinay Prasad
and
Timothée Olivier
5
Share this post
Special post-ASCO 2024 edition !
www.drugdevletter.com
Copy link
Facebook
Email
Note
Other
2
45:27
My 2 hour lecture at ASCO on Critical Appraisal
My thank you to supporters
Jun 6
•
Vinay Prasad
11
Share this post
My 2 hour lecture at ASCO on Critical Appraisal
www.drugdevletter.com
Copy link
Facebook
Email
Note
Other
Share
Copy link
Facebook
Email
Note
Other
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
